UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.
20549
___________________
FORM 8-K
___________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of report (date of earliest event reported): June 5, 2017
OWC
Pharmaceutical Research Corp.
(Exact Name of
Registrant as Specified in its Charter)
Commission File No.: 0-54856
Delaware | 98-0573566 |
(State of Incorporation) | (I.R.S. Employer Identification No.) |
30 Shacham Street. P.O.B. 8324 Petach Tikva, Israel | 4918103 |
(Address of Principal Executive Offices) | (ZIP Code) |
Registrant's Telephone Number, including area code: 972 (0) 3-758-2657
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨ Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01. Other Events. The Registrant has determined to evaluate the potential
benefits of cross listing its shares of common stock, currently subject to
quotation on the OTCQB: OWCP, for listing on a Canadian stock exchange, such
as the Toronto Stock Exchange, among others. We believe that cross listing
may improve the Registrant's access to capital and liquidity. To this end,
the Registrant has agreed to engage a major national Canadian law firm with
specific expertise in venture capital markets to assist us in achieving a
listing on a Canadian exchange.
SIGNATURES Pursuant to the requirements of the Securities Exchange
Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
OWC Pharmaceutical Research Corp. | ||
By: /s/ Mordechai Bignitz | ||
Name: Mordechai Bignitz | ||
Title: Chief Executive Officer |
Date: June 7, 2017